# Neuromuscular Junction

> Neuromuscular junction transmission steps, acetylcholine release, end plate potential, myasthenia and drugs for MBBS Physiology.

- Canonical URL: https://prepelephant.com/topics/mbbs/physiology/neuromuscular-junction
- Exam / course: MBBS · Subject: Physiology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Neuromuscular Junction", PrepElephant, https://prepelephant.com/topics/mbbs/physiology/neuromuscular-junction

## Direct answer

The neuromuscular junction is the chemical synapse between the axon terminal of a motor neuron and the specialised junctional folds of the muscle fibre sarcolemma, together called the motor end plate. An action potential arriving at the terminal opens calcium channels, acetylcholine is released in quanta and binds nicotinic receptors on the end plate, and the resulting end-plate potential, which is a local, graded potential, fires a muscle action potential that triggers contraction.

## What you must remember

- **Sequence of transmission:** nerve action potential, calcium influx through voltage-gated channels, exocytosis of acetylcholine vesicles, binding to nicotinic receptors, end-plate potential, muscle action potential, and contraction.
- **Quantal release:** acetylcholine is stored in vesicles, each holding several thousand molecules; a single vesicle released spontaneously produces a miniature end-plate potential of under a millivolt.
- **The receptor:** the nicotinic receptor at the end plate is a ligand-gated channel permeable to both sodium and potassium; its opening locally depolarises the end plate.
- **Safety factor:** a nerve impulse releases many vesicles, so the end-plate potential is several times larger than the threshold needed to fire the adjacent sarcolemma — transmission normally never fails.
- **Termination:** acetylcholinesterase in the basement membrane hydrolyses the transmitter within milliseconds, so the muscle can respond to the next impulse.
- **Pharmacology:** botulinum toxin blocks release; d-tubocurarine competitively blocks the receptor; organophosphates irreversibly inhibit acetylcholinesterase; neostigmine, an anticholinesterase, improves transmission in myasthenia gravis.
- **Clinical:** myasthenia gravis — antibodies against nicotinic receptors causing fatigable weakness, improved by neostigmine; Lambert-Eaton syndrome — antibodies against the presynaptic calcium channels, improving with activity rather than worsening.

## Common confusion

The end-plate potential and the muscle action potential are conflated. The end-plate potential is local, graded and non-propagated, caused by a non-selective cation flux, while the muscle action potential is all-or-none and propagated by voltage-gated sodium channels in the sarcolemma beside the end plate. Students also confuse the two immunological syndromes — in myasthenia the weakness worsens with repeated activity because the damaged receptors fail, whereas in Lambert-Eaton repeated activity temporarily improves strength because more calcium accumulates in the terminal.

## Exam-focused takeaway

In theory, list the steps in order with the ionic basis at each step, then classify drugs and toxins by their site of action and finish with myasthenia gravis. In viva, expect the difference between EPP and action potential, why neostigmine helps myasthenia but may cause cholinergic excess, and what organophosphate poisoning does at the junction. In practicals and OSCE stations, demonstrate the fatigability of ptosis in a myasthenic patient and explain the ice-pack or the neostigmine test you would apply.

## Frequently asked questions

### What are the steps of transmission at the neuromuscular junction?

A nerve action potential opens calcium channels, acetylcholine is released, it binds nicotinic receptors on the end plate, an end-plate potential is generated, and a muscle action potential and contraction follow. Acetylcholinesterase then terminates the signal.

### What is a miniature end-plate potential?

The tiny depolarisation produced by the spontaneous release of a single vesicle of acetylcholine. It demonstrated that transmitter is released in packets or quanta, not continuously.

### Why does transmission never fail normally?

Because each nerve impulse releases enough vesicles to generate an end-plate potential far above the threshold of the sarcolemma — the high safety factor. Failure appears only in diseases like myasthenia gravis.

### How do curare and organophosphates act here?

Curare competes with acetylcholine for the nicotinic receptor and causes flaccid paralysis. Organophosphates irreversibly inhibit acetylcholinesterase, causing persistent depolarisation, fasciculations and then paralysis.

### How does myasthenia gravis differ from Lambert-Eaton syndrome?

Myasthenia gravis is postsynaptic, with antibodies against the nicotinic receptors, so weakness worsens with activity. Lambert-Eaton is presynaptic, with antibodies against calcium channels, and strength briefly improves with repeated activity.